CRSP — Crispr Therapeutics AG Income Statement
0.000.00%
Last trade - 00:00- $3.31bn
- $1.40bn
- $37.31m
- 43
- 15
- 85
- 45
Annual income statement for Crispr Therapeutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.719 | 915 | 1.2 | 371 | 37.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 355 | 541 | 674 | 594 | 504 |
| Operating Profit | -354 | 374 | -673 | -223 | -467 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -348 | 380 | -651 | -151 | -363 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -349 | 378 | -650 | -154 | -366 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -349 | 378 | -650 | -154 | -366 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -349 | 378 | -650 | -154 | -366 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.29 | 4.7 | -8.36 | -1.94 | -4.34 |